Stock listing

NASDAQ:HCWB HCW Biologics Inc. Stock

Home listing (NASDAQ) of HCW Biologics Inc.

Follow HCW Biologics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:HCWB

$0.749 USD -0.015 (-1.9%)

Close on Nov 20, 2026

Past year -93.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.700 – $0.795 USDNov 20, 2026
Volume
23,620 sharesNov 20, 2026
Market cap
$2.35M USDAt the close on Nov 20, 2026 · price × 3.14M shares outstanding
52-week range
$0.700 – $23.940 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$760,531 USDMedian day 59,529 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
HCW Biologics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:HCWB · Home$0.749 USD-0.015 (-1.9%)23,620$0.720$0.795$0.700$0.764Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:HCWB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.749-0.015-1.9%$0.720$0.795$0.70023,620
$0.764-0.013-1.6%$0.777$0.840$0.75819,733
$0.777-0.023-2.9%$0.810$0.817$0.77715,175
$0.800+0.027+3.5%$0.840$0.846$0.74387,029
$0.773-0.027-3.4%$0.807$0.857$0.77322,272
$0.801-0.059-6.9%$0.894$0.894$0.76436,105
$0.860-0.080-8.5%$0.950$0.996$0.86035,538
$0.940-0.014-1.5%$0.959$1.000$0.94020,983
$0.954-0.066-6.5%$1.010$1.055$0.95042,849
$1.020-0.020-1.9%$1.025$1.045$1.01022,434
$1.040-0.040-3.7%$1.110$1.110$1.01088,075
$1.080-0.070-6.1%$1.100$1.150$1.08017,600
$1.150+0.030+2.7%$1.180$1.180$1.09037,764
$1.120+0.020+1.8%$1.110$1.280$1.11073,686
$1.100-0.080-6.8%$1.160$1.189$1.10034,188
$1.180-0.040-3.3%$1.160$1.220$1.16033,151
$1.220+0.080+7.0%$1.160$1.240$1.16059,529
$1.140+0.040+3.6%$1.150$1.150$1.10019,915
$1.100-0.070-6.0%$1.180$1.180$1.10030,444
$1.170+0.050+4.5%$1.120$1.191$1.09080,400
$1.120-0.040-3.4%$1.150$1.150$1.10045,600
$1.160-0.010-0.9%$1.170$1.210$1.15049,700
$1.170-0.060-4.9%$1.250$1.270$1.17097,900
$1.230-0.010-0.8%$1.240$1.340$1.23098,900
$1.240+0.010+0.8%$1.230$1.270$1.22077,700
$1.230+0.060+5.1%$1.170$1.280$1.15048,500
$1.170-0.090-7.1%$1.241$1.260$1.14057,500
$1.260-0.220-14.9%$1.300$1.450$1.2502,129,900
$1.480-0.120-7.5%$1.560$1.600$1.47043,000
$1.600+0.070+4.6%$1.600$1.728$1.52079,900
$1.530-0.030-1.9%$1.590$1.610$1.51046,400
$1.560-0.010-0.6%$1.550$1.620$1.54030,600
$1.570-0.070-4.3%$1.610$1.630$1.55037,700
$1.640-0.040-2.4%$1.640$1.690$1.55082,000
$1.680-0.010-0.6%$1.660$1.721$1.65064,600
$1.690-0.020-1.2%$1.747$1.747$1.67155,100
$1.710-0.040-2.3%$1.770$1.823$1.71048,200
$1.750-0.070-3.8%$1.810$1.850$1.75051,400
$1.820-0.110-5.7%$1.860$1.895$1.710102,200
$1.930-0.060-3.0%$1.880$2.000$1.810416,900
$1.990+0.330+19.9%$1.690$3.120$1.67013,666,200
$1.660-0.150-8.3%$1.810$1.830$1.610161,200
$1.810-0.100-5.2%$1.910$1.980$1.700132,900
$1.910+0.040+2.1%$1.950$2.020$1.87059,100
$1.870-0.080-4.1%$2.000$2.150$1.87087,500
$1.950-0.060-3.0%$2.050$2.074$1.94066,700
$2.010-0.040-2.0%$2.090$2.100$1.89086,500
$2.050-0.150-6.8%$2.170$2.189$2.05055,300
$2.200-0.040-1.8%$2.240$2.325$2.18097,800
$2.240-0.190-7.8%$2.430$2.445$2.16093,900
$2.430-0.030-1.2%$2.420$2.520$2.41029,200
$2.460-0.050-2.0%$2.440$2.530$2.340102,100
$2.510-0.430-14.6%$2.520$2.720$2.1003,078,600
$2.940+0.070+2.4%$2.810$2.970$2.80035,600
$2.870-0.485-14.5%$3.340$3.340$2.700127,100
$3.355-0.095-2.8%$3.540$3.810$3.320207,900
$3.450-0.140-3.9%$3.510$3.730$3.300543,900
$3.590+0.160+4.7%$3.600$3.600$3.21158,600
$3.430+0.260+8.2%$3.200$3.430$3.000120,200
$3.170+0.470+17.4%$2.700$3.280$2.600332,400
$2.700+0.100+3.8%$2.690$2.700$2.55060,600
$2.600+0.290+12.6%$2.310$2.888$2.280278,800
$2.310+0.130+6.0%$2.320$2.323$2.150307,700
$2.180+0.060+2.8%$2.160$2.230$2.05055,500
$2.120-0.180-7.8%$2.260$2.380$2.06090,100

Splits

2 splits since 2025 · NASDAQ:HCWB · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
1-for-40Consolidation
Ticker
NASDAQ:HCWB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All HCW Biologics Inc. news

HCW Biologics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 92 in all · newest Nov 16, 2026 · oldest 2021
Decks
2 decks · latest March 2026

Where HCW Biologics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:HCWB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:HCWBBOATSUnited StatesUSD

Valuation

EV/sales 1.2× against a median of 28.0×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$8.23M USD
P/E
Loss
EV/sales
1.2×
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
96.6%
Operating margin
−103.9%
Net margin
−63.4%
Debt to equity
1.0×
Beta vs S&P 500
1.19

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
Median of the othersUS$2.39M−US$907,8680.7×28.0×0.3×−540.4%0.0×1.41

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
48.00 USD · Analysts' mean
EPS, year to Dec 2026
-28.32 · 1 analyst
Revenue, year to Dec 2026
6.68M · 1 analyst

Team and board

Officers

OfficerRole
Hing C. WongChief Executive Officer
Rebecca ByamChief Financial Officer
Jack EganVice President of Manufacturing and Development
Lee FlowersSenior Vice President Business Development
Nicole ValdiviesoVice President Legal Affairs
Peter RhodeChief Scientific Officer and Vice President Clinical Operations

Board

DirectorRole
Hing C. WongChief Executive Officer
Lisa M. GilesBoard Member
Rick S. Greene
Scott T. GarrettBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open+3.5%
Q2 2026Aug 14, 2026 · After close−6.0%
Q1 2026May 14, 2026 · After close+262.0%
Q3 2025Nov 14, 2025 · After close+2.0%
Q2 2025Aug 18, 2025 · After close−11.4%
Q1 2025May 15, 2025+1.6%
Q4 2024Mar 28, 2025 · After close−6.0%
Q3 2024Nov 14, 2024 · After close−4.5%
Q2 2024Aug 14, 2024 · After close−13.6%
Q1 2024Apr 1, 2024 · After close+0.6%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 26, 2024+2.9%
Q3 2023Nov 14, 2023 · Before open−17.7%
Q2 2023Aug 11, 2023 · Before open+3.9%
Q1 2023May 9, 2023 · Before open+4.9%
Q4 2022Mar 28, 2023 · After close+9.8%
Q3 2022Nov 7, 2022 · After close−2.2%
Q2 2022Aug 12, 2022 · Before open+8.0%
Q1 2022May 13, 2022 · Before open−1.0%
Q4 2021Mar 29, 2022 · Before open+2.1%
Quarter to Sep 30, 2021Nov 12, 2021 · Before open+1.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck20 slidesMarch 2026
IPO Roadshow (July 2021)IPO roadshow12 slidesJul 12, 2021

Open Decks

Financings

RaiseDate
Debt financing
Closed: US$3M raised
Use of proceeds: Fund clinical and operating activities to complete the Phase 1 study of HCW9302 in alopecia areata and establish the Recommended Phase 2 Dose
Nov 5, 2026
Private placement of units (pre-funded warrants with rights to common warrants)
Announced: US$1.5M · US$1.6599 a unit · Warrants at US$1.66 for 66 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes
Sep 24, 2026
Private placement of units (common stock or pre-funded warrants, with common warrants)
Announced: US$1.6M · US$2.585 a unit · Warrants at US$2.585 for 66 months
Buyers: Hing C. Wong, Ph.D.; Scott Garrett; Lee Flowers
Insiders: CEO Hing C. Wong, Chairman Scott Garrett and SVP Lee Flowers participated on the same terms
Use of proceeds: Continue HCW9302 clinical trials, advance IND-enabling studies for HCW11-018b and HCW11-040, and general corporate purposes
Jul 29, 2026
Public offering of units (one share of common stock or pre-funded warrant and one warrant)
Announced: about US$1.5M · US$0.6055 a unit · 1 warrant at US$0.6055 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Preclinical and clinical development, including HCW9302 clinical trials, and general corporate purposes
Feb 18, 2026
Warrant exercise of common stock upon exercise of outstanding warrants
Announced: about US$4M · US$2.66 a share · ½ warrant at US$2.41 for 66 months · Maxim Group LLC
Dealers: Maxim Group LLC
Nov 19, 2025
Public offering of units (one share of common stock or pre-funded warrant and two warrants)
Closed: US$5M raised · US$7.45 a unit · Warrants at US$7.45 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Open clinical sites for the Phase 1 trial of HCW9302 in an autoimmune disorder
May 15, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a share on Jul 19, 2021.

Price
US$8.00 a share
Shares offered
7,000,000 shares of common stock
Offering size
US$56 million
Underwriters' option
Up to 1,050,000 more shares
Underwriters
EF HUTTON, REVERE SECURITIES LLC · In the order on the cover
Shares delivered
On or about Jul 22, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceApr 16, 2021
Filed publiclyMay 26, 2021
Amended 3 timesNewest Jul 9, 2021
Shares registered with an exchangeJul 9, 2021
Declared effective by the SECJul 19, 2021
Final prospectus, with the priceJul 21, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 21, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue54.2K2.57M2.84M6.72M04.10M0
Cost of revenue43.4K1.61M2.28M4.14M0421.8K
Gross profit10.8K959.4K560.4K2.59M04.10M-421.8K
Research and development5.44M6.39M7.68M9.34M8.17M7.26M5.14M
Selling, general and administrative7.70M21.9M13.1M7.99M5.09M2.44M1.80M
Operating income-13.2M-29.5M-25.7M-15.1M-13.4M-5.82M-7.37M
Depreciation and amortization1.04M1.18M1.14M717.9K543.6K572.9K421.8K
EBITDA-12.1M-28.3M-24.6M-14.4M-12.8M-5.25M-6.94M
Interest expense845.1K654.3K283.0K126.7K000
Income before tax-7.96M-30.0M-25.0M-14.9M-12.9M-5.80M-7.29M
Income tax000000-72.4K
Net income-7.96M-30.0M-25.0M-14.9M-12.9M-5.80M-7.29M
Earnings per share, basic-10.63-30.96-0.70-0.42-0.69-1.49-1.19
Earnings per share, diluted-10.63-30.96-0.70-0.42-0.69-1.49

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents1.95M4.67M3.60M22.3M11.7M8.46M7.36M
Short-term investments0009.74M25.0M0
Receivables32.2K582.2K1.54M417.7K133.0K2.50M
Inventory1.39M2.20M538.3K
Current assets2.28M5.70M6.40M34.1M40.5M12.1M8.03M
Property, plant and equipment20.9M22.9M20.5M10.8M1.12M1.62M2.00M
Total assets24.5M30.2M28.5M46.8M53.5M15.4M10.1M
Accounts payable13.1M22.3M6.17M1.23M223.7K155.3K392.3K
Current liabilities21.1M29.6M8.75M2.96M2.32M1.00M1.07M
Long-term debt7.38M6.30M6.41M
Total debt6.81M13.7M6.30M6.41M0567.3K
Total liabilities21.8M37.0M15.1M9.38M2.32M1.00M1.07M
Shareholders' equity2.76M-6.77M13.5M37.4M51.2M-16.7M9.00M
Shares outstanding3.14M3.14M6.73M44.9M37.8M35.9M6.12M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-13.4M-14.2M-22.5M-10.4M-11.0M-10.4M-6.77M
Capital spending0-261.6K-6.20M-10.3M-47.3K-186.7K-1.46M
Free cash flow-13.4M-14.5M-28.7M-20.7M-11.0M-10.6M-8.23M
Cash from investing0-261.6K3.80M14.7M-35.0M-186.7K-1.46M
Cash from financing10.7M15.6M-14.5K6.27M49.3M11.7M13.4M
Dividends paid-2.82M
Share buybacks-174.8K
Change in cash-2.72M1.08M-18.7M10.6M3.27M1.10M5.22M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Meeting outcomeSEC
PRE 14A · Preliminary proxy statementNov 18, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
8-K · Current reportNov 5, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveOct 13, 2026Other filingsSEC
CORRESP · Letter to the SECOct 8, 2026Other filingsSEC
UPLOAD · Letter from the SECOct 8, 2026Other filingsSEC
DOct 8, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
S-1 · Registration statementOct 2, 2026Offer documentSEC
DEF 14A · Proxy statementOct 1, 2026Meeting noticeSEC
8-K · Current reportSep 24, 2026Material contractSEC
8-K · Current reportSep 9, 2026Current reportSEC
PRER14ASep 9, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Material contractSEC
PRE 14A · Preliminary proxy statementSep 4, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveSep 1, 2026Other filingsSEC
CORRESP · Letter to the SECAug 28, 2026Other filingsSEC
S-1/A · Registration statement, amendedAug 28, 2026Offer documentSEC
UPLOAD · Letter from the SECAug 26, 2026Other filingsSEC
S-1 · Registration statementAug 20, 2026Offer documentSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q/A · Quarterly report, amendedAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026Current reportSEC
DAug 6, 2026Other filingsSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
8-K · Current reportJul 29, 2026Material contractSEC
POS AM · Amendment to an effective registrationJul 16, 2026Offer documentSEC
8-K · Current reportJul 1, 2026Current reportSEC
8-K · Current reportJun 30, 2026Current reportSEC
8-K · Current reportJun 26, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJun 22, 2026Other filingsSEC
S-1/A · Registration statement, amendedJun 18, 2026Offer documentSEC
CORRESP · Letter to the SECJun 16, 2026Other filingsSEC
8-K · Current reportJun 16, 2026Current reportSEC
8-K · Current reportJun 15, 2026Meeting outcomeSEC
UPLOAD · Letter from the SECJun 12, 2026Other filingsSEC
DJun 8, 2026Other filingsSEC
S-1 · Registration statementJun 8, 2026Offer documentSEC
8-K · Current reportJun 1, 2026Current reportSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
8-K · Current reportMay 27, 2026Current reportSEC
8-K · Current reportMay 21, 2026Material contractSEC
POS AM · Amendment to an effective registrationMay 18, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
POS AM · Amendment to an effective registrationMay 13, 2026Offer documentSEC
8-K · Current reportApr 30, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
8-K · Current reportApr 29, 2026Current reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
S-1/A · Registration statement, amendedApr 24, 2026Offer documentSEC
S-1 · Registration statementApr 23, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 16, 2026Current reportSEC
DRS · Draft registration statementApr 10, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 17, 2026Material contractSEC
DEF 14A · Proxy statementMar 13, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 3, 2026Meeting noticeSEC
8-K · Current reportMar 2, 2026Current reportSEC
8-K · Current reportFeb 19, 2026Material contractSEC
424B4 · ProspectusFeb 19, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
S-1/A · Registration statement, amendedFeb 17, 2026Offer documentSEC
S-1/A · Registration statement, amendedFeb 13, 2026Offer documentSEC
8-K · Current reportFeb 13, 2026Material contractSEC
CORRESP · Letter to the SECFeb 11, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 11, 2026Other filingsSEC
S-1 · Registration statementFeb 11, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 30, 2026Other filingsSEC
CORRESP · Letter to the SECJan 27, 2026Other filingsSEC
S-1 · Registration statementJan 9, 2026Offer documentSEC
8-K · Current reportDec 31, 2025Current reportSEC
DRS · Draft registration statementDec 19, 2025Offer documentSEC
8-K · Current reportNov 20, 2025Material contractSEC
8-K · Current reportNov 18, 2025Material contractSEC
8-K · Current reportNov 18, 2025Current reportSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportNov 14, 2025ResultsSEC
8-K · Current reportOct 16, 2025Current reportSEC
DRS · Draft registration statementSep 30, 2025Offer documentSEC
8-K · Current reportSep 5, 2025Material contractSEC
8-K · Current reportAug 19, 2025Current reportSEC
10-Q · Quarterly reportAug 18, 2025Quarterly reportSEC
8-K/A · Current report, amendedAug 18, 2025ResultsSEC
NT 10-Q · Late filing noticeAug 15, 2025Explanation requestSEC
8-K · Current reportAug 14, 2025Material contractSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportJul 18, 2025Material contractSEC
8-K · Current reportJul 1, 2025Current reportSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 23, 2025Management or board changeSEC
8-K · Current reportJun 13, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 13, 2025Big-stake noticeSEC
8-K · Current reportJun 5, 2025Current reportSEC
8-K · Current reportJun 4, 2025Material contractSEC
8-K · Current reportMay 30, 2025Current reportSEC
8-K · Current reportMay 23, 2025Current reportSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
8-K · Current reportMay 20, 2025Current reportSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
8-K · Current reportMay 15, 2025Material contractSEC
424B4 · ProspectusMay 15, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 15, 2025Other filingsSEC
S-1/A · Registration statement, amendedMay 13, 2025Offer documentSEC
CORRESP · Letter to the SECMay 13, 2025Other filingsSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
4 · Change in ownershipMay 9, 2025Insider tradeSEC
CORRESP · Letter to the SECMay 9, 2025Other filingsSEC
S-1 · Registration statementMay 9, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 1, 2025Other filingsSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DRS · Draft registration statementApr 25, 2025Offer documentSEC
8-K · Current reportApr 22, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 17, 2025Other filingsSEC
424B3 · ProspectusApr 16, 2025Offer documentSEC
CORRESP · Letter to the SECApr 15, 2025Other filingsSEC
8-K · Current reportApr 14, 2025Material contractSEC
UPLOAD · Letter from the SECApr 8, 2025Other filingsSEC
S-1 · Registration statementApr 7, 2025Offer documentSEC
8-K · Current reportApr 1, 2025Current reportSEC
8-K · Current reportApr 1, 2025Meeting outcomeSEC
10-K · Annual reportMar 28, 2025Annual reportSEC
8-K · Current reportMar 28, 2025ResultsSEC
8-K · Current reportMar 19, 2025Material contractSEC
8-K · Current reportMar 6, 2025Current reportSEC
CT ORDERFeb 26, 2025Other filingsSEC
DEFR14AFeb 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementFeb 21, 2025Meeting noticeSEC
8-K · Current reportFeb 21, 2025Material contractSEC
PRE 14A · Preliminary proxy statementFeb 11, 2025Meeting noticeSEC
8-K · Current reportFeb 7, 2025Current reportSEC
8-K · Current reportFeb 3, 2025Current reportSEC
8-K · Current reportDec 23, 2024Current reportSEC
DDec 5, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedNov 22, 2024Big-stake noticeSEC
8-K · Current reportNov 22, 2024Current reportSEC
8-K · Current reportNov 20, 2024Material contractSEC
424B2 · ProspectusNov 20, 2024Offer documentSEC
8-K · Current reportNov 18, 2024Material contractSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
8-K · Current reportSep 20, 2024Current reportSEC
8-K/A · Current report, amendedAug 23, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K · Current reportAug 12, 2024Current reportSEC
8-K · Current reportJul 18, 2024Material contractSEC
8-K · Current reportJun 20, 2024Current reportSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
4 · Change in ownershipJun 17, 2024Insider tradeSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
ARS/A · Annual report to shareholders, amendedMay 20, 2024Annual reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-K/A · Annual report, amendedMay 15, 2024Annual reportSEC
8-K · Current reportMay 3, 2024Current reportSEC
8-K · Current reportMay 1, 2024Current reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
8-K · Current reportApr 1, 2024ResultsSEC
DFeb 27, 2024Other filingsSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
8-K · Current reportFeb 22, 2024Material contractSEC
8-K · Current reportJan 12, 2024Current reportSEC
4 · Change in ownershipDec 11, 2023Insider tradeSEC
4 · Change in ownershipDec 11, 2023Insider tradeSEC
4 · Change in ownershipNov 20, 2023Insider tradeSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC
4 · Change in ownershipOct 23, 2023Insider tradeSEC

This page holds 200 of 348 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from HCW Biologics Inc.’s releases · as of Nov 11, 2026

Common shares
3,139,938
Fully diluted
3,139,938

Fully diluted

LineSharesAs of
Common shares3,139,938Nov 11, 2026

Warrants and options

Lot
Warrants · US$7.45 · expire about May 2030

Share count over time

CountShares
Nov 11, 20263,139,938
Jun 26, 2026

Open Cap table

Shareholders

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund32,1381.0%US$63,633May 31, 2026
Fidelity Total Market Index Fund7260.02%US$1,437May 31, 2026
Fidelity Nasdaq Composite Index Fund4120.01%US$816May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Garrett Scott T
Director
Buy7,736USD 2.59US$20,036Jul 29, 2026
Flowers Lee
Officer: SVP of Business Development
Buy7,736USD 2.59US$20,036Jul 29, 2026
Wong Hing C
Director, Officer: Chief Executive Officer, 10% owner
Buy23,210USD 2.59US$60,114Jul 29, 2026
Byam Rebecca
Officer: Chief Financial Officer
Buy14,235USD 1.41US$20,071May 22, 2026
Garrett Scott T
Director
Buy177,936USD 1.41US$251KMay 22, 2026
Wong Hing C
Director, Officer: Chief Executive Officer, 10% owner
Buy113,879USD 1.41US$161KMay 22, 2026

Big stakes

StakeStakeSharesDateFiling
Hing C. Wong, Ph.D.23.38%502KMay 15, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary M. Winer
Other companies: LENSAR, Inc. (Director · Since at least Sep 17, 2020)
Director · Oct 26, 2021 – May 16, 2025 · Past
Scott T. Garrett
Other companies: Hologic Inc (Director · Dec 11, 2023 – Mar 14, 2024 · Past)
Director · Since at least Feb 20, 2024
Hing C. WongChief Executive Officer, Director · Since at least May 7, 2025
Jack EganVice President of Manufacturing and Development · Since at least Nov 4, 2026
Jin-an JiaoVP of Development · May 31, 2022 – May 31, 2022 · Past
Lee FlowersSenior Vice President Business Development · Since at least Jul 31, 2026
Lisa M. GilesBoard Member · Since at least Nov 5, 2026
Nicole ValdiviesoVice President Legal Affairs · Since at least Nov 4, 2026
Peter RhodeChief Scientific Officer and Vice President Clinical Operations · Since at least Nov 17, 2023
Rebecca ByamChief Financial Officer · Since at least May 27, 2026
All 12 people
PersonSeat
Rick S GreeneDirector · Jun 2, 2022 – May 7, 2025 · Past
Rick S. GreeneDirector · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about HCW Biologics Inc.